Tadalafil
Product Images NDC 63629-7943

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 63629-7943). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 01

Chemical structure of tadalafil, illustrating the molecular framework with fused rings including a substituted piperazine and indole moieties.*

FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 02

A forest plot chart illustrating the mean differences in blood pressure measurements comparing tadalafil and placebo across various coadministered drugs and dosages. The x-axis shows the difference in blood pressure changes, with confidence intervals for each condition listed on the y-axis, including standing, supine, and ambulatory systolic and diastolic BP values.*

FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 03

A forest plot chart showing fold changes and 90% confidence intervals in the pharmacokinetics of Tadalafil when coadministered with various drugs. It categorizes coadministered drugs into CYP3A inhibitors, CYP3A inducers, antacids, and H2 antagonists. The x-axis shows change relative to Tadalafil alone, and the chart includes dosing recommendations such as dose adjustment, avoid use, or no dose adjustment for each drug interaction.*

FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 04

A forest plot chart showing fold change and 90% confidence intervals comparing coadministered drugs relative to each drug alone. The chart includes various substrates such as CYP1A2, CYP2C9, CYP3A, CYP2C9/CYP3A, P-glycoprotein, oral contraceptives, and NSAIDs, with recommendations stating no dose adjustment for each substrate. The x-axis represents change relative to the coadministered drug alone from 0.00 to 2.00.*

FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 05

A line graph comparing the mean change from baseline in meters over 16 weeks between two groups: Placebo (82 participants) and Tadalafil 40 mg (79 participants). The graph shows increasing improvements for the Tadalafil group over time, with statistical significance noted at weeks 4, 8, 12, and 16 (p-values ranging from 0.0152 to 0.0004). Error bars represent variability within each group.*

FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 06

A forest plot illustrating the placebo-adjusted mean change in 6-minute walk distance for subjects treated with ADCIRCA 40mg compared to placebo. The plot shows various subgroups, including bosentan use, PAH etiology, baseline walk distance, gender, age, and baseline WHO functional class, with 95% confidence intervals and number of subjects for each group.*

FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 07

A line graph showing the percentage of subjects without clinical worsening over time in days. Three lines compare Tadalafil 40 mg, Tadalafil 20 mg, and placebo groups, illustrating time to clinical worsening.*

FDA Label Image

Label Image (Lbl636297943)

Label for Tadalafil 20mg Tablet by Bryant Ranch Prepack. The label indicates the product compares to Cialis 20mg Tablet by Cipla Ltd. It includes storage instructions to keep at 20°-25°C (68°-77°F) and a warning to keep drugs out of reach of children. Package size is 30 tablets. The NDC is 63629-7943-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.